When was Biogen founded?

Biogen was founded in 1978 and raised its 1st funding round 5 years after it was founded.

Where is Biogen located?

Biogen is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Biogen have?

As of Sep 30, 2024, the latest employee count at Biogen is 1.

Is Biogen a funded company?

Biogen is a funded company, having raised a total of $80M across 3 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Feb 19, 1983.

When was the latest funding round of Biogen?

Biogen's latest funding was a $***** Post IPO round on Feb 13, 2024, with participation from 1 investor.

What is the annual revenue of Biogen?

Annual revenue of Biogen is $9.68B as on Dec 31, 2024.

Where does Biogen rank among its competitors?

Biogen ranks 132nd amongst 3123 active competitors, of which 1083 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Biogen, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of Biogen?

Biogen's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Biogen secured the most recent funding round in February, 2024.

Biogen - 2026 Company Profile, Team, Funding, Competitors & Financials

Biogen is a public company based in Cambridge (United States), founded in 1978 by Phillip Allen Sharp, Walter Gilbert, Heinz, Kenneth Murray and Charles Weissmann. It operates as a Developer of therapies for neurodegenerative and immunology disorders. Biogen has raised $80M in funding. The company has 3123 active competitors, including 1083 funded and 779 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.

Company Details

Developer of therapies for neurodegenerative and immunology disorders. The company has developed a pipeline of drugs for Alzheimer's disease Amyotrophic lateral sclerosis (ALS), Angelman syndrome, Brain contusion, Multiple sclerosis (MS), Multiple system atrophy (MSA), Ophthalmology, Pain, and more.

Website: www.biogen.com/
Social
Email ID: *****@biogen.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

1978

Location

Cambridge, United States

Stage

Public

Total Funding

$80M in 3 rounds

Latest Funding Round

Post IPO, Feb 13, 2024, $*****

Investors

Berkshire Hathaway & 11 more

Ranked

132^nd among 3123 active competitors

Annual Revenue

$9.68B as on Dec 31, 2024

Employee Count

1 as on Sep 30, 2024

Investment & Acquisitions

Apellis Pharmaceuticals & 41 more

Similar Companies

Jazz Pharmaceuticals & 998 more

Exit Details

Public

View Biogen's full profile

Biogen is associated with 7 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Biogen Inc. CIN: 875045 , United States, Active	Sep 22, 2014	$9.68B (As on Dec 31, 2024)	-	-
BIOGEN IDEC BIOTECH INDIA PRIVATE LIMITED CIN: U24232DL2007PTC305611 , India, Active	Mar 01, 2007	$0 (As on Mar 31, 2025)	-
Biogen Idec Inc. CIN: 330112644 , United States, Active	Dec 31, 1999	$9.7B (As on Dec 31, 2014)	4289 (As on Dec 31, 2024)	-
BIOGEN CAPABILITY CENTER INDIA PRIVATE LIMITED CIN: U62013KA2023FTC173057 , India, Active	Apr 30, 2023	$7.85M (As on Mar 31, 2025)	-
Biogen Estonia OÜ CIN: 14996084 , Estonia, Active	Jun 24, 2020	-	1 (As on Sep 30, 2024)
BIOGEN PHARMA D.O.O. CIN: 76730068664 , Croatia, Active	Feb 17, 2020	$1.06M (As on Dec 31, 2024)	-
Biogen Ma Inc. CIN: 20151245297 , United States, Active	Apr 08, 2015	-	-	-

Biogen got listed on Sep 16, 1991.

Click here to take a look at Biogen's IPO in detail

Biogen has raised a total funding of $80M over 3 rounds. Its first funding round was on Feb 19, 1983. Its latest funding round was a Post IPO round on Feb 13, 2024 for $*****. 1 investor participated in its latest round. Biogen has 12 institutional investors.

Here is the list of recent funding rounds of Biogen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 13, 2024	1919355	Post IPO	9823002	3897112	8499556	5187097
Jul 27, 2010	4650244	Grant (prize money)	9440617	7910189	1470853	HHS
Feb 19, 1983	9987890	PE	6851454	6597810	2257964	9590318

Access funding benchmarks and valuations. Sign up today!

View details of Biogen's funding rounds and investors

The founders of Biogen are Phillip Allen Sharp, Walter Gilbert, Heinz, Kenneth Murray and Charles Weissmann.

Here are the details of Biogen's key team members:

Phillip Allen Sharp: Co-Founder of Biogen and founder of 1 other company.
Contact Info: 1 email address
Walter Gilbert: Co-Founder of Biogen.
Contact Info: 1 email address
Heinz: Co-Founder of Biogen.
Kenneth Murray: Former Co-Founder of Biogen.
Charles Weissmann: Co-Founder of Biogen.
Contact Info: 1 email address

View details of Biogen's Founder profiles and Board Members

Biogen's employee count trend

Biogen has 1 employees as of Sep 24. The total employee count is 50.0% lower than what it was in Sep 23. Here is Biogen's employee count trend over the years:

Uncover Biogen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biogen include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Biogen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	HBM Healthcare Investments, Orbimed & 6 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
9th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	71/100
10th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
132nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 10 others	64/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Biogen's competitors? Click here to see the top ones

Biogen has made 29 investments in companies including Dayra Therapeutics and Autobahn Therapeutics. Biogen has also acquired 13 companies including Apellis Pharmaceuticals and Alcyone.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Mar 31, 2026	Acquisition	Apellis Pharmaceuticals	2008	Crestwood (United States)
Nov 24, 2025	Investments	Dayra Therapeutics		San Francisco (United States)
Sep 18, 2025	Acquisition	Alcyone	2010	Lowell (United States)